In the News: China Biotech FDI; US Lithium Battery Factories; and Chinese Pharma in the UK

May 29, 2024 | BY

Clarence Lee

Western companies are investing in Chinese biotech even amid continued geopolitical tension between China and the West and decreasing appetite for foreign investment in China; Two lithium battery part manufacturers, Capchem and Kedaliplan, plan to build factories in the U.S. to avoid hefty lithium battery tariffs; and Chinese pharma firm Asymchem to take over U.K. Pfizer plant.

Paulista/Adobe Stock

|

More Western Companies Invest in China Biotech

Four Western life science investors are entering a licensing deal with Chinese drugmaker Jiangsu Hengrui Pharmaceuticals for $400 million, an indication of the growing trend of out-licensing deals by Chinese biotech firms, Biopharma Drive reported.

This premium content is reserved for
China Law & Practice Subscribers.

  • A database of over 3,000 essential documents including key PRC legislation translated into English
  • A choice of newsletters to alert you to changes affecting your business including sector specific updates
  • Premium access to the mobile optimized site for timely analysis that guides you through China's ever-changing business environment
For enterprise-wide or corporate enquiries, please contact our experienced Sales Professionals at +44 (0)203 868 7546 or [email protected]